Peptide Database

FPF 1070

Cerebrolysin is a mixture of neuropeptides and neurotrophic factors derived from porcine brain proteins. It mimics the actions of endogenous neurotrophic factors (NGF, BDNF, CNTF), promoting neuronal survival, synaptogenesis, and neuroplasticity. Approved in multiple countries for Alzheimer's disease, stroke recovery, and TBI, clinical trials show improvements in cognitive function, activities of daily living, and brain MRI outcomes.

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408

Dihexa is a small peptide derived from angiotensin IV that acts as a potent agonist at the HGF/c-Met receptor system, which mediates synaptogenesis — the formation of new synaptic connections. Animal studies suggest it may be several orders of magnitude more potent than BDNF at promoting synapse formation. Research focuses on Alzheimer's disease, cognitive decline, and traumatic brain injury.

N-phenylacetyl-L-prolylglycine ethyl ester · GVS-111

Noopept is a dipeptide-derived nootropic approved in Russia for cognitive disorders and memory impairment. It is hydrolyzed in vivo to release cycloprolylglycine, an endogenous neuropeptide. Research demonstrates neuroprotective, memory-enhancing, and anxiolytic effects, upregulation of BDNF and NGF in the hippocampus and cortex, and potential benefits in Alzheimer's disease models. It is significantly more potent than piracetam on a weight-for-weight basis.

P21 cognitive peptide

P21 is a peptide fragment derived from CNTF (Ciliary Neurotrophic Factor) designed to activate the STAT3 signaling pathway, which promotes neurogenesis and cognitive function. Animal research demonstrates improved spatial memory, increased hippocampal neurogenesis, and enhanced BDNF expression. It is studied as a non-cytokine CNTF functional mimetic without the systemic side effects of full-length CNTF.

Selanc · TP-7

Selank is a synthetic heptapeptide analog of tuftsin developed by the Russian Institute of Molecular Genetics. Approved in Russia for anxiety and cognitive disorders, it exhibits anxiolytic effects comparable to benzodiazepines without sedation or dependence. Research shows it modulates GABA, serotonin, and dopamine systems, enhances BDNF expression, and improves memory consolidation and learning.

C₃₃H₅₇N₁₁O₉ · 751.87 Da

MEHFPGP · Pro8-Gly9-Pro10-ACTH(4–10)

Semax is a synthetic heptapeptide analog of ACTH(4-7) developed in Russia, where it is approved for stroke, TBI, peptic ulcers, and cognitive enhancement. It upregulates BDNF and its receptor TrkB, promotes dopamine and serotonin turnover, and has demonstrated neuroprotective effects in ischemia models. Research highlights improvements in attention, memory, and recovery from neurological injury.